Morrison Foerster is an international law firm with lawyers practicing throughout the United States, Asia, and Europe. Click to discover more.

mofo_share_image.jpg

Morrison Foerster

common-default.jpeg

Terms / Notices

Cookies

Privacy Policy

Reporting Hotline

Attorney Advertising

Alumni

  Linkedin

MoFo LinkedIN

  Facebook

MoFo Facebook

YouTube

MoFo Youtube

Morrison Foerster - Footer

MoFo Advises Ally Bridge Group on Investment in Imperative Care

You have not solved the recaptcha challenge yet or session expired, try again.

Email Disclaimer

Disclaimer

Unsolicited e-mails and information sent to Morrison Foerster will not be considered confidential, may be disclosed to others pursuant to our <a href="https://www.mofo.com/about/privacy-policy.html">Privacy Policy</a>, may not receive a response, and do not create an attorney-client relationship with Morrison Foerster. If you are not already a client of Morrison Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

Feedback

mofo-logo-2022.svg

People

Capabilities

Resources

About

Culture

Offices

Careers

Stay Connected

Morrison & Foerster advised Ally Bridge Group in connection with a Series C financing round totaling $85 million in Imperative Care, an innovative startup that is dedicated to improving the way ischemic and hemorrhagic strokes are treated.

About Morrison Foerster

people-default-header-desktop.jpg

people-default-header-mobile.jpg

Default Meta Data

Morrison & Foerster advised Ally Bridge Group in connection with a Series C financing round totaling $85 million in Imperative Care, an innovative startup that is dedicated to improving the way ischemic and hemorrhagic strokes are treated. Announced on December 10, 2019, the round was co-led by Ally Bridge and Bain Capital Life Sciences. This marks the third investment that MoFo has closed on behalf of Ally Bridge since April 2019.Founded in 2016 by Dr. Nick Hopkins, a pioneer of endovascular neurointervention, and medtech entrepreneur Fred Khosravi, Imperative Care is developing a portfolio of solutions to address the vast and urgent unmet needs in stroke care. The company says it will use the funds to support the commercial launch of its breakthrough technologies.The cross-border, cross-practice MoFo team was led by Hong Kong corporate partner Thomas Chou and included corporate associates Cecile Yang in Hong Kong and Connor Acle and Olga Terets in San Francisco, patent partner Janet Xiao and associate John Chapman in Palo Alto, and FDA regulatory partner Bethany Hills in New York.Read the related <a href="https://www.businesswire.com/news/home/20191210005092/en/Imperative-Care-Announces-85-Million-Series-Financing" target="_blank">press release</a>.

MoFo Advises Ally Bridge Group on Investment in Imperative Care

Sign Up

Thomas has devoted more than a quarter century to advising sophisticated and impactful clients to complete complex, market-leading transactions globally, with deep experience in the U.S. and Asia Pacific region. He concentrates his practice on cross-border mergers and acquisitions, joint ventures, and emerging company and venture capital advisory and transactional work. Thomas’ clients include industry-leading emerging growth companies and a broad range of investors who fund them (traditional private equity and venture capital funds, prominent Asian family offices, the corporate/strategic investment arms of large corporates, insurance companies, and sovereign wealth funds). His broad industry coverage includes biopharma, MedTech and digital health; mobile, gaming, and entertainment; material science and semiconductors (equipment and design); Deeptech/AI; Fintech (payments, remittances, and digital assets); PropTech; FoodTech; health and wellness; and consumer products and retail.Clients and outside ranking organizations routinely cite Thomas’ accomplishments:<ul><li>Thomas is “a strong advocate for his client, offering strategic and actionable advice, evaluating and clearly prioritizing the key issues in complex situations and proactively anticipating concerns from counterparties in negotiations."</li><li>“Thomas Chou is excellent in understanding the industry and leads the team in working on the same. He is very responsive and works 24 hours responding to the clients.”</li><li>“Thomas has significant experience handling complex cross–border transactions across the Asia–Pacific region. His counsel is frequently sought by global technology corporations to advise on their investments in the region. He also commands considerable respect from private equity clients.”</li><li>His clients pinpoint his “decades of venture capital experience both in the United States and in Asia,” with one noting: “He is patient, attentive to details and someone who has clearly conquered many battlefields.”</li><li>Thomas is particularly praised for his communications skills, with clients saying, “Any issues we had he would always provide a solution. He is not only interpreting regulations, but he is also commercially savvy.”</li></ul>At MoFo, Thomas is an active member of our Emerging Company + Venture Capital, Private Equity, and M&A practices, all of which are consistently highly ranked in major independent industry league tables and lawyer ranking organizations.Thomas is also a proud member of the board of directors of the Starlight Children’s Foundation.

周至恒（Thomas Chou）律师在公司业务领域非常活跃，重点处理跨境并购（中国境内外）、合资、私募股权和风险资本融资业务。他的客户包括新兴成长型公司，传统以及非传统投资者（私募股权和风险投资基金，家族办公室，公司/公司的战略投资部门，金融机构以及主权财富基金）。他的执业领域主要是技术、媒体和电信、医疗和生命科学以及消费和零售业。客户和外部评级机构都经常称赞周律师的成就：<ul><li>“周律师在处理亚太地区复杂跨境交易方面经验丰富，全球科技公司常因在该地区的投资而寻求其意见，他也广受私募股权客户推崇。”</li><li>“（周律师）资历深厚，精于各种风险投资及私募股权事宜，包括前期与后期的投资及并购，他在科技领域的经验尤其丰富。”</li><li>客户赞赏他“在美国及亚洲均有数十年风险投资经验”，并称其“非常耐心，注重细节，实战经验丰富”。</li><li>周律师的沟通技巧尤其为人所称道，他的客户指出：“不管我们出现任何问题，周律师都能提出解决方案。他不仅能准确把握法律条文，同时极具商业头脑。”</li></ul>周律师是美富亚洲私募股权业务的联席主管，也是新兴公司 + 风险投资业务组和并购业务组的活跃成员。他在上述业务领域均持续受到独立的法律行业排行榜和律师评级机构的高度认可。周律师还是星光儿童基金会的董事会成员。

Thomas Chou

Partner

Janet focuses her practice on worldwide patent procurement, patent portfolio management, and strategic planning for life sciences companies. Janet’s clients range from large multinational biopharmaceutical companies, such as Celgene and Genentech, to emerging startup companies around the world. She advises her clients on patent matters relating to various technologies, including antibody therapeutics, cell therapeutics, nanomedicine, gene therapy, drug delivery systems, diagnostics, and nutraceuticals.Recognized by Chambers as being highly sought after for patent prosecution and strategy mandates by innovators from around the world, Janet develops and strengthens her clients’ complex patent portfolios to maximize their commercial value. She is instrumental in developing strategies for multibillion-dollar patent portfolios for pharmaceutical clients. As impressed clients noted to Chambers, “Janet’s work is thorough, polished and always of the highest caliber. She is well equipped to advise international clients on patent prosecution and strategy in the biotech industry, drawing on substantial technical knowledge.”Janet works extensively in performing IP due diligence reviews in the contexts of VC investments, technology transactions, mergers and acquisitions, and marketing and manufacturing clearance for biopharmaceutical products. She helps some of the world’s most-sophisticated biopharmaceutical companies and investors assess potential risks and devise preemptive risk-management strategies for their product development and investments. She has led hundreds of IP due diligence projects, and is noted for her in-depth knowledge of patent landscapes in the fields of cancer immunotherapy, gene editing, next-generation sequencing, liquid biopsy, antibody manufacturing, and medical devices. Janet works regularly with patent litigators in the event of legal challenges by third-party competitors or vice versa, and she is frequently called upon to represent clients in litigation and post-grant proceedings.Janet is the Head of firm’s China Life Sciences Group and served as co-chair of the global Life Sciences Group from 2016 to 2019. She is among the very few IP attorneys in the world who are both equipped with solid skills in global strategic IP management and knowledgeable about IP issues unique to China and Chinese clients, and she has been the go-to counsel for IP issues in U.S./China cross-border transactions and operations in China. Chambers Global praises her as an outstanding IP lawyer “who is renowned for her work on IP issues concerning complex cross-border transactions, where she regularly advises Chinese clients.” In a recent edition of Chambers Global, a client says, “Janet . . . is very experienced in advising life sciences clients doing business in China and the US . . . She is highly responsive and always gives practical advice. Her IP expertise adds tremendous value to our business.”Since 2005, Janet has been actively involved in the leadership team of the Chinese-American Biopharmaceutical Society (CABS), a nonprofit organization dedicated to bridging the life sciences communities in the U.S. and China, including serving as president for the 2011–2012 term. She is also a member of BayHelix, a nonprofit organization of Chinese heritage leaders in the global life sciences and healthcare fields.

肖荐（Janet Xiao）博士的业务侧重于为生命科学公司处理在全球范围内的专利采购、专利组合管理和战略策划事宜。肖博士服务的客户范围广泛，包括大型跨国生物制药公司，例如赛尔基因公司（Celgene）和基因泰克公司（Genentech），也包括全球范围的新兴创业公司。她经常就与各种技术有关的专利事宜向客户提供法律意见，其中涉及的技术包括抗体疗法、细胞疗法、纳米医学、基因疗法、给药系统、诊断和和营养学等。来自全球的创新者纷纷向肖博士寻求专利申请和专利战略的法律咨询，这一点也得到了《钱伯斯指南》的认可。她帮助客户开发和加强其复杂的专利组合，从而为客户实现最大的商业价值。在为制药行业的客户制定数十亿美元专利组合的战略方面，肖博士发挥着重要的作用。《钱伯斯指南》曾引用客户评价称，“肖博士是我曾合作过的律师当中知识最渊博、效率最高的一位律师。她能很好地将专利组合的历史信息用于全球专利申请问题上。”肖博士针对风险投资、技术交易、并购和生物医药产品的市场推广与生产许可事宜开展广泛的知识产权尽职调查审查工作。她协助世界上一些最成功的生物制药公司和投资者，为其产品开发和投资评估潜在风险，并制定先发制人的风险管理策略。她曾牵头处理过数百个知识产权尽职调查项目，并凭借自己对癌症免疫治疗、基因编辑、新一代测序、液体活检、抗体制造和医疗设备领域的专利方面的深厚知识而闻名。肖博士时常与专利诉讼律师合作，处理由第三方竞争者提出的法律质疑，或对第三方竞争者提出的法律质疑，她还经常受聘代表客户处理专利诉讼和授予后程序。肖博士是美富中国生命科学业务组主管，她曾在2016至2019期间担任美富全球生命科学业务组的联席主管。肖博士是全球为数不多的既拥有很强的全球战略性知识产权管理技能，同时又对中国和中国客户独特的知识产权问题具有深刻理解的知识产权律师之一，她一直是处理中美跨境交易和在中国境内经营中所涉知识产权问题的首选律师。《钱伯斯全球指南》称赞她是一位优秀的知识产权律师，“她因处理与复杂跨境交易有关的知识产权问题工作而知名，经常代表中国客户处理这方面的事宜” 。在近期一版《钱伯斯全球指南》中，某客户评价称，“肖博士在为于中国和美国开展业务的生命科学客户提供法律意见方面，有非常丰富的经验。她非常负责而且总是提供切实可行的法律意见。她在知识产权方面的专业意见为我们的业务增添了巨大价值。”自2005年以来，肖博士一直积极参与北美华人生物医药协会（CABS）的领导工作。该协会是一家非营利组织，致力于成为连接中美两国生命科学领域的纽带。肖博士在2011至2012年间担任该协会主席。她还是百华协会（BayHelix）的成员。百华协会是一家非营利组织，由全球生命科技和医疗保健产业领域的华人精英组成。

Janet Xiao

Dr. Chapman provides patent and intellectual property services to clients on pharmaceutical, chemistry, biotechnology, and medical device matters.He is experienced in drafting patent applications, proactively prosecuting domestic and foreign patent applications, and assisting with due diligence and freedom-to-operate assessments. Dr. Chapman is committed to providing responsive client service utilizing the firm’s collective legal and scientific capabilities. Since joining the firm in 2013, he has worked with a variety of clients including startup biotechnology, chemistry, and medical device companies; large pharmaceutical companies; academic institutions; and independent inventors. Dr. Chapman’s scientific education includes studies in medicinal chemistry, proteomics, mass spectrometry instrumentation and application, biochemistry, pharmacology, molecular biology, and chemistry. His technical background also includes training and research conducted at: the David R. Goodlett Laboratory (utilized mass spectrometry instrumentation to identify novel protein pathway responses and protein post-translational modifications); Amgen (utilized mass spectrometry instrumentation to study antibody-drug conjugates); and the Southwest Environmental Health Sciences Center (studied protein adduction by environmental toxicants).He is admitted to practice in California and before the U.S. Patent & Trademark Office.

John Chapman

Associate

Life Sciences + Healthcare

Emerging Companies + Venture Capital